|Articles|February 19, 2020
White Matter Hyperintensities May Increase Risk of Levodopa-Induced Dyskinesia in Parkinson Disease
Author(s)Marco Meglio
Patients with Parkinson disease with moderate to severe white matter hyperintensity (WMH) burden had a greater risk of developing levodopa-induced dyskinesia compared with those with minimal WMHs.
Advertisement
Han Soo Yoo, MD
New study results suggest that the burden of white matter hyperintensities is associated with risk of developing levodopa-induced dyskinesia (LID) in patients with Parkinson disease (PD).
The study included 336 patients with drug-naïve early stage PD who were treated PD medication for at least 3 years to assess the association between WMH and the risk of LID in patients with PD.
Brian magnetic resonance imaging (MRI) scans, including fluid‐attenuated inversion recovery (FLAIR) sequence images, and 18F‐N‐(3‐fluoropropyl)‐2β‐carbon ethoxy‐3β‐(4‐iodophenyl) nortropane (18F‐FP‐CIT) positron emission tomography (PET), were completed upon initial assessment. Each patient was rated on FLAIR images using the Clinical Research Center for Dementia of South Korea (CREDOS) WMH visual rating scale.
Ultimately, 227 patients were classified as having minimal WMHs and 109 were classified as having moderate to severe WMHs. Notably, those with moderate to severe WMH were older, had higher scores on the Unified Parkinson’s Disease Rating Scale-3, and were more likely to have hypertension and diabetes.
Investigators rated periventricular and lobar (frontal, parietal, temporal, and occipital) WMHs, as well as separately rating basal ganglia and infratentorial signal hyperintensities.
READ MORE: Outpatient Palliative Care Model Shows Potential for Parkinson Disease and Related Disorders
Cox regression analysis was used to assess the regional WMH burden on the development of LID, with adjustments for age at PD onset, sex, dopamine transporter availability in the posterior putamen, and levodopa-equivalent doses per body weight.
Results from the Kaplan-Meier analysis showed that those with moderate to severe WMHs had a greater risk of developing LID than those with minimal WMHs (Pl < .001). When the model was adjusted for age at PD onset, sex, baseline striatal dopamine depletion, and levodopa-equivalent doses per body weight, the hazard ratio (HR) for developing LID after initiation of PD medication in the moderate to severe group compared with the minimal group was 2.660 (95% CI, 1.742-4.062; P <.001).
Data from the Cox regression model showed a correlation between greater WMH burden and greater risk of developing LID in either overall samples (HR 1.044; 95% CI, 1.018-1.071; P = .001) and propensity score subsamples (HR 1.040; 95% CI, 1.012—1.069; P = .005).
“Based on previous and current studies, the WMH burden seems to be an important clinical parameter, acting as a predictor of parkinsonian motor outcome, as well as LID development in patients with PD,” the study authors wrote. “These findings suggest that baseline WMHs can act as a predictive marker or therapeutic target for the development of LID in patients with early stage PD.”
REFERENCE
Chung SJ, Yoo HS, Lee YH, et al. White matter hyperintensities and risk of levodopa-induced dyskinesia in Parkinson’s disease. Ann Clin Transl Neurol. Published online February 7, 2020. doi: 10.1002/acn3.50991.
Newsletter
Keep your finger on the pulse of neurology—subscribe to NeurologyLive for expert interviews, new data, and breakthrough treatment updates.
Advertisement
Related Articles
- This Week on NeurologyLive® — September 15, 2025
September 15th 2025
- NeurologyLive® Brain Games: September 14, 2025
September 14th 2025
- NeurologyLive® Friday 5 — September 12, 2025
September 12th 2025
Latest CME
Advertisement
Advertisement
Trending on NeurologyLive
1
MDA and PPMD Release Consensus Guidelines for Safe and Equitable Use of Gene Therapy in Duchenne
2
10 Years of the Women Neurologists Group: A Preview of the 4th Annual Conference
3
DORAs Carry Lower Real-World Abuse, New Phase 3 Argus Data, RAP-219 Meets Primary End Point
4